Solventum (NYSE:SOLV) Updates FY 2026 Earnings Guidance

Solventum (NYSE:SOLV) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 7.100-7.200 for the period, compared to the consensus estimate of 6.550. The company issued revenue guidance of -.

Analyst Ratings Changes

Several brokerages recently commented on SOLV. KeyCorp increased their price objective on shares of Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Weiss Ratings upgraded shares of Solventum from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, July 17th. UBS Group upgraded Solventum from a “neutral” rating to a “buy” rating and set a $95.00 target price on the stock in a research note on Tuesday, July 28th. Stifel Nicolaus reduced their price target on shares of Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Finally, Piper Sandler dropped their target price on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Seven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Solventum currently has an average rating of “Hold” and a consensus price target of $86.00.

Solventum Stock Performance

Shares of NYSE SOLV traded down $0.68 during trading on Wednesday, hitting $87.26. The company had a trading volume of 1,552,465 shares, compared to its average volume of 1,084,826. The stock has a 50 day simple moving average of $79.09 and a 200 day simple moving average of $74.36. The firm has a market capitalization of $15.11 billion, a P/E ratio of 10.69, a price-to-earnings-growth ratio of 1.36 and a beta of 0.60. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. Solventum has a 12 month low of $62.38 and a 12 month high of $88.65.

Solventum (NYSE:SOLV) last released its earnings results on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.64. The company had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.15 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The firm’s revenue was up 2.2% compared to the same quarter last year. During the same quarter last year, the business earned $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, analysts anticipate that Solventum will post 6.58 earnings per share for the current year.

Solventum News Roundup

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Second-quarter adjusted earnings per share were $2.55, well above analysts’ expectations of approximately $1.90-$1.91. Revenue reached $2.21 billion, exceeding the $2.15 billion consensus estimate. Solventum Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Sales increased 2.2% year over year, while organic sales growth was a stronger 9.5%, suggesting improving underlying demand despite reported revenue growth being affected by portfolio or currency factors. Solventum Q2 Earnings Metrics
• Positive Sentiment: Solventum raised its full-year 2026 guidance, including adjusted EPS of $7.10-$7.20 versus consensus near $6.55-$6.58. The company also increased expectations for organic sales growth and free cash flow, strengthening the earnings outlook. Solventum Raises Profit Forecast
• Neutral Sentiment: The company intends to separate its Health Information Systems business, positioning Solventum as a more focused medical-technology company while allowing the healthcare software unit to pursue its own growth strategy. The move could unlock shareholder value, but investors will watch the separation’s structure, costs and execution. Solventum Health Information Systems Separation

Institutional Trading of Solventum

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. United Services Automobile Association bought a new stake in shares of Solventum during the first quarter valued at approximately $239,000. Woodline Partners LP increased its holdings in Solventum by 40.7% in the 1st quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock valued at $888,000 after acquiring an additional 3,377 shares during the last quarter. Intech Investment Management LLC lifted its stake in Solventum by 167.0% in the 1st quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock worth $1,268,000 after purchasing an additional 10,425 shares in the last quarter. First Trust Advisors LP lifted its stake in Solventum by 5.8% in the 2nd quarter. First Trust Advisors LP now owns 257,727 shares of the company’s stock worth $19,546,000 after purchasing an additional 14,151 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Solventum during the 2nd quarter valued at about $766,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.